Muscle Proteomic Profile before and after Enzyme Replacement Therapy in Late-Onset Pompe Disease

Int J Mol Sci. 2021 Mar 11;22(6):2850. doi: 10.3390/ijms22062850.


Mutations in the acidic alpha-glucosidase (GAA) coding gene cause Pompe disease. Late-onset Pompe disease (LOPD) is characterized by progressive proximal and axial muscle weakness and atrophy, causing respiratory failure. Enzyme replacement therapy (ERT), based on recombinant human GAA infusions, is the only available treatment; however, the efficacy of ERT is variable. Here we address the question whether proteins at variance in LOPD muscle of patients before and after 1 year of ERT, compared withhealthy age-matched subjects (CTR), reveal a specific signature. Proteins extracted from skeletal muscle of LOPD patients and CTR were analyzed by combining gel based (two-dimensional difference gel electrophoresis) and label-free (liquid chromatography-mass spectrometry) proteomic approaches, and ingenuity pathway analysis. Upstream regulators targeting autophagy and lysosomal tethering were assessed by immunoblotting. 178 proteins were changed in abundance in LOPD patients, 47 of them recovered normal level after ERT. Defects in oxidative metabolism, muscle contractile protein regulation, cytoskeletal rearrangement, and membrane reorganization persisted. Metabolic changes, ER stress and UPR (unfolded protein response) contribute to muscle proteostasis dysregulation with active membrane remodeling (high levels of LC3BII/LC3BI) and accumulation of p62, suggesting imbalance in the autophagic process. Active lysosome biogenesis characterizes both LOPD PRE and POST, unparalleled by molecules involved in lysosome tethering (VAMP8, SNAP29, STX17, and GORASP2) and BNIP3. In conclusion this study reveals a specific signature that suggests ERT prolongation and molecular targets to ameliorate patient's outcome.

Keywords: autophagy; mass spectrometry; pompe disease; proteomics; rare disease; sarcopenia.

MeSH terms

  • Adult
  • Autophagy
  • Chromatography, Liquid / methods
  • Electrophoresis, Gel, Two-Dimensional / methods
  • Enzyme Replacement Therapy / methods*
  • Female
  • Glucan 1,4-alpha-Glucosidase / genetics
  • Glucan 1,4-alpha-Glucosidase / therapeutic use*
  • Glycogen Storage Disease Type II / therapy*
  • Humans
  • Lysosomes / metabolism
  • Male
  • Microscopy, Electron, Transmission
  • Muscle Proteins / metabolism
  • Muscle, Skeletal / metabolism*
  • Muscle, Skeletal / ultrastructure
  • Proteome / metabolism
  • Proteomics / methods*
  • Recombinant Proteins / therapeutic use
  • Tandem Mass Spectrometry / methods


  • Muscle Proteins
  • Proteome
  • Recombinant Proteins
  • Glucan 1,4-alpha-Glucosidase